trial · primary record
Liposomal Irinotecan Plus Cisplatin
Advanced Solid Malignancies
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 44 |
| Primary completion | 2032-12-31 |
| Primary endpoint | Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) |
| Registry ID | NCT07782346 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:05.361Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07782346
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.